Cooley Advises Special Committee of Checkpoint on Acquisition by Sun Pharma

New York – March 9, 2025 – Cooley advised the independent special committee of Checkpoint Therapeutics’ (Nasdaq: CKPT) board of directors in connection with Checkpoint’s definitive agreement to be acquired by Sun Pharmaceutical Industries (NSE: SUNPHARMA) for an upfront cash payment of $4.10 per share and an up-to 70-cent nontransferable contingent value right, representing an aggregate transaction value of up to $416 million. Checkpoint is a commercial-stage company focused on developing novel treatments for patients with solid tumor cancers.

The transaction is subject to customary closing conditions, including required regulatory approvals, approval by the holders of a majority of the voting power of outstanding shares of Checkpoint common stock, and approval by the holders of a majority of the shares of Checkpoint common stock that are not held by Fortress Biotech (Nasdaq: FBIO), Checkpoint’s controlling stockholder, or by certain other Checkpoint affiliates.

Lawyers Bill Roegge, Kevin Cooper, Marc Recht, Wesley Dietrich and Katie Benvenuti led the Cooley team advising the special committee.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.